Pharmala Biotech Holdings Inc.
MDXXF
$0.07
$0.000.00%
OTC PK
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 147.90K | 194.90K | 96.10K | 101.80K | 41.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 147.90K | 194.90K | 96.10K | 101.80K | 41.70K |
| Cost of Revenue | 25.00K | 24.80K | 6.80K | 6.60K | -- |
| Gross Profit | 122.90K | 170.10K | 89.30K | 95.10K | 41.70K |
| SG&A Expenses | 306.30K | 349.50K | 361.70K | 555.90K | 303.80K |
| Depreciation & Amortization | 21.30K | 21.30K | 20.70K | 20.30K | 21.50K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 382.00K | 428.30K | 443.60K | 645.30K | 349.50K |
| Operating Income | -234.10K | -233.40K | -347.50K | -543.60K | -307.80K |
| Income Before Tax | -293.50K | -263.30K | -372.90K | -566.50K | -348.30K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -293.50K | -263.30K | -372.90K | -566.50K | -348.30K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -293.50K | -263.30K | -372.90K | -566.50K | -348.30K |
| EBIT | -234.10K | -233.40K | -347.50K | -543.60K | -307.80K |
| EBITDA | -224.30K | -223.80K | -338.20K | -534.40K | -286.30K |
| EPS Basic | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 108.01M | 99.06M | 105.28M | 101.76M | 92.08M |
| Average Diluted Shares Outstanding | 108.01M | 99.06M | 105.28M | 101.76M | 92.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |